Equities research analysts at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN – Get Free Report) in a report released on Thursday. The firm set a “sell” rating on the stock.
Oragenics Price Performance
OGEN stock opened at $0.42 on Thursday. Oragenics has a 52-week low of $0.38 and a 52-week high of $7.74. The company has a 50-day moving average of $0.85 and a two-hundred day moving average of $1.22. The stock has a market capitalization of $2.34 million, a price-to-earnings ratio of -0.05 and a beta of 0.50.
Oragenics (NYSE:OGEN – Get Free Report) last announced its quarterly earnings data on Friday, August 9th. The company reported ($0.51) EPS for the quarter.
Institutional Inflows and Outflows
About Oragenics
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Further Reading
- Five stocks we like better than Oragenics
- 3 REITs to Buy and Hold for the Long Term
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- Find and Profitably Trade Stocks at 52-Week Lows
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.